Carbapenem-Resistant Enterobacter Infections

Patients with imipenem-resistant Enterobacter infections were more likely than those with imipenem-susceptible Enterobacter infections to have multiple invasive devices and to die in-hospital.

Carbapenems are often cited as the drugs of choice for serious Enterobacter infections, and resistance has rarely been seen. However, from April 2003 through December 2006, 33 patients at a Tel Aviv, Israel, hospital contracted infections with imipenem-resistant Enterobacter (IRE). In a case-control study, researchers compared these individuals to 33 patients who contracted imipenem-susceptible Enterobacter (ISE) infections at the same hospital during the same period. Patients and controls were matched by age group and source of culture.

All 33 IRE isolates were ertapenem-resistant; 21 were meropenem-resistant, 4 were meropenem-intermediate, and 8 were deemed meropenem-susceptible but with an elevated MIC (4–6 µg/mL). Multidrug resistance wa…

Reviewing Author

Lynn L. Estes, PharmD

Disclosures

Editorial boardsMayo Clinic Antimicrobial Therapy Quick Guide

Lynn L. Estes, PharmD

Disclosures

Editorial boardsMayo Clinic Antimicrobial Therapy Quick Guide